146 related articles for article (PubMed ID: 1859299)
1. Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.
Sparks DL; Woeltz VM; Markesbery WR
Arch Neurol; 1991 Jul; 48(7):718-21. PubMed ID: 1859299
[TBL] [Abstract][Full Text] [Related]
2. Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Chan-Palay V; Höchli M; Savaskan E; Hungerecker G
Dementia; 1993; 4(1):1-15. PubMed ID: 8358501
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical and histopathologic alterations characteristic of Pick's disease in a non-demented individual.
Sparks DL; Danner FW; Davis DG; Hackney C; Landers T; Coyne CM
J Neuropathol Exp Neurol; 1994 Jan; 53(1):37-42. PubMed ID: 8301318
[TBL] [Abstract][Full Text] [Related]
4. Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.
Sherif F; Gottfries CG; Alafuzoff I; Oreland L
J Neural Transm Park Dis Dement Sect; 1992; 4(3):227-40. PubMed ID: 1627256
[TBL] [Abstract][Full Text] [Related]
5. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.
Oreland L; Gottfries CG
Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):533-40. PubMed ID: 3797686
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
[TBL] [Abstract][Full Text] [Related]
7. Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias.
Jaisa-Aad M; Muñoz-Castro C; Healey MA; Hyman BT; Serrano-Pozo A
Acta Neuropathol; 2024 Apr; 147(1):66. PubMed ID: 38568475
[TBL] [Abstract][Full Text] [Related]
8. Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Zellner M; Baureder M; Rappold E; Bugert P; Kotzailias N; Babeluk R; Baumgartner R; Attems J; Gerner C; Jellinger K; Roth E; Oehler R; Umlauf E
J Proteomics; 2012 Apr; 75(7):2080-92. PubMed ID: 22270014
[TBL] [Abstract][Full Text] [Related]
9. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease.
Sparks DL; Hunsaker JC; Slevin JT; DeKosky ST; Kryscio RJ; Markesbery WR
Ann Neurol; 1992 Jun; 31(6):611-20. PubMed ID: 1355334
[TBL] [Abstract][Full Text] [Related]
10. Neuropathological study on the nucleus basalis of Meynert in Pick's disease.
Mizukami K; Kosaka K
Acta Neuropathol; 1989; 78(1):52-6. PubMed ID: 2735190
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):382-391. PubMed ID: 27633250
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer's Disease.
Rahman MS; Uddin MS; Rahman MA; Samsuzzaman M; Behl T; Hafeez A; Perveen A; Barreto GE; Ashraf GM
Curr Pharm Des; 2021; 27(38):4017-4029. PubMed ID: 34126892
[TBL] [Abstract][Full Text] [Related]
13. Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease.
Bonuccelli U; Piccini P; Marazziti D; Cassano GB; Muratorio A
J Neural Transm Park Dis Dement Sect; 1990; 2(2):139-47. PubMed ID: 2222781
[TBL] [Abstract][Full Text] [Related]
14. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Gulyás B; Pavlova E; Kása P; Gulya K; Bakota L; Várszegi S; Keller E; Horváth MC; Nag S; Hermecz I; Magyar K; Halldin C
Neurochem Int; 2011 Jan; 58(1):60-8. PubMed ID: 21075154
[TBL] [Abstract][Full Text] [Related]
15. Altered serotonergic and cholinergic synaptic markers in Pick's disease.
Sparks DL; Markesbery WR
Arch Neurol; 1991 Aug; 48(8):796-9. PubMed ID: 1898253
[TBL] [Abstract][Full Text] [Related]
16. Biphasic and region-specific MAO-B response to aging in normal human brain.
Saura J; Andrés N; Andrade C; Ojuel J; Eriksson K; Mahy N
Neurobiol Aging; 1997; 18(5):497-507. PubMed ID: 9390776
[TBL] [Abstract][Full Text] [Related]
17. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
18. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Borroni E; Bohrmann B; Grueninger F; Prinssen E; Nave S; Loetscher H; Chinta SJ; Rajagopalan S; Rane A; Siddiqui A; Ellenbroek B; Messer J; Pähler A; Andersen JK; Wyler R; Cesura AM
J Pharmacol Exp Ther; 2017 Sep; 362(3):413-423. PubMed ID: 28642233
[TBL] [Abstract][Full Text] [Related]
19. Neuropathologic changes of the temporal pole in Alzheimer's disease and Pick's disease.
Arnold SE; Hyman BT; Van Hoesen GW
Arch Neurol; 1994 Feb; 51(2):145-50. PubMed ID: 8304839
[TBL] [Abstract][Full Text] [Related]
20. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
